Egis Developing Business Abroad
Hungarian pharmaceutical comp-any Egis Gyogyszergyar is looking to strengthen its sales in eastern and western Europe this year. The firm is likely to acquire the eastern European network of Medimpex, the former Hungarian monopoly for foreign trade in pharmaceutical products, according to a report in New Europe.
This means that Egis could strengthen its sales in Russia, which is likely to be the key element of a successful sales strategy in the Commonwealth of Independent States, said the report.
The firm is also in a position to get access to new markets in western Europe as a result of its strategic alliance with French pharmaceutical firm Servier (Marketletter January 1 & 8).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze